Bupropion - Revision history

Elcatracho: /* Pediatric Dosing */

2021-02-22T04:43:09Z

Pediatric Dosing

← Older revision		Revision as of 04:43, 22 February 2021
Line 11:		Line 11:

	==Pediatric Dosing==		==Pediatric Dosing==
	''Safety/efficacy not established]]		''Safety/efficacy not established

	==Special Populations==		==Special Populations==

Elcatracho: /* Contraindications */

2021-02-09T15:30:45Z

Contraindications

← Older revision		Revision as of 15:30, 9 February 2021
Line 23:		Line 23:
	*Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks		*Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks
	*Seizure disorder		*Seizure disorder
	*Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, benzos, or AEDs, anorexia/bulimia, electrolyte derangement)		*Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, [[Benzodiazepines\|benzos]], or AEDs, [[Anorexia nervosa\|anorexia]]/[[Bulimia nervosa\|bulimia]], electrolyte derangement)

	==Adverse Reactions==		==Adverse Reactions==

Elcatracho: /* Mechanism of Action */

2021-01-13T18:05:29Z

Mechanism of Action

← Older revision		Revision as of 18:05, 13 January 2021
Line 50:		Line 50:
	*Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine		*Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine
	*Structurally belongs to the class of [[Synthetic Cathinones\|synthetic cathinones]]		*Structurally belongs to the class of [[Synthetic Cathinones\|synthetic cathinones]]
			**Due to structure, can cause false positive screen for amphetamine on UDS<ref>Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105-108. doi:10.1007/s13181-010-0131-5</ref>

	==Comments==		==Comments==

Elcatracho: /* Pharmacology */

2021-01-13T18:04:51Z

Pharmacology

← Older revision		Revision as of 18:04, 13 January 2021
Line 46:		Line 46:
	*Metabolism: Hepatic, CYP2B6		*Metabolism: Hepatic, CYP2B6
	*Excretion: Mostly renal		*Excretion: Mostly renal
	*Can cause false positive screen for amphetamine on UDS<ref>Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105-108. doi:10.1007/s13181-010-0131-5</ref>

	==Mechanism of Action==		==Mechanism of Action==

Elcatracho: /* Pharmacology */

2021-01-13T18:03:32Z

Pharmacology

← Older revision		Revision as of 18:03, 13 January 2021
Line 46:		Line 46:
	*Metabolism: Hepatic, CYP2B6		*Metabolism: Hepatic, CYP2B6
	*Excretion: Mostly renal		*Excretion: Mostly renal
			*Can cause false positive screen for amphetamine on UDS<ref>Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105-108. doi:10.1007/s13181-010-0131-5</ref>

	==Mechanism of Action==		==Mechanism of Action==

Elcatracho: /* Mechanism of Action */

2020-11-26T01:10:55Z

Mechanism of Action

← Older revision		Revision as of 01:10, 26 November 2020
Line 49:		Line 49:
	==Mechanism of Action==		==Mechanism of Action==
	*Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine		*Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine
			*Structurally belongs to the class of [[Synthetic Cathinones\|synthetic cathinones]]

	==Comments==		==Comments==

ClaireLewis at 21:39, 19 September 2019

2019-09-19T21:39:04Z

← Older revision		Revision as of 21:39, 19 September 2019
Line 57:		Line 57:
	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Psychiatry]]

Humanguy: edited dosage forms, strengths, routes of administration, trade names

2017-10-11T23:31:42Z

edited dosage forms, strengths, routes of administration, trade names

← Older revision		Revision as of 23:31, 11 October 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Antidepressant		*Type: Antidepressant
	*Dosage Forms:		*Dosage Forms: tablet, sustained-release tablet, extended-release tablet
	*Routes of Administration: ~~oral~~		*Dosage Strengths: tablet: 75, 100mg; sustained-release tablet (Wellbutrin SR): 100, 150, 200mg; extended-release tablet (Wellbutrin XL): 150, 300mg; extended-release tablet (Aplenzin): 174, 348, 522mg; extended-release tablet (Forfivo XL): 450mg; extended-release tablet (Zyban): 150mg
	*Common Trade Names: Wellbutrin, Zyban, Forfivo		*Routes of Administration: PO
			*Common Trade Names: Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Forfivo XL, Budeprion SR, Aplenzin, Buproban

	==Adult Dosing==		==Adult Dosing==

ClaireLewis: Created page with "==Administration== Type: Antidepressant Dosage Forms: Routes of Administration: oral Common Trade Names: Wellbutrin, Zyban, Forfivo ==Adult Dosing== *Immediate release: 1..."

2016-12-26T23:58:05Z

Created page with "==Administration== *Type: Antidepressant *Dosage Forms: *Routes of Administration: oral *Common Trade Names: Wellbutrin, Zyban, Forfivo ==Adult Dosing== *Immediate release: 1..."

New page

==Administration==
*Type: Antidepressant
*Dosage Forms:
*Routes of Administration: oral
*Common Trade Names: Wellbutrin, Zyban, Forfivo

==Adult Dosing==
*Immediate release: 100-150mg PO 2-4 times daily
*Sustained release: 150mg PO 1-2 times daily

==Pediatric Dosing==
''Safety/efficacy not established]]

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out
*Renal dosing: dose reduction or avoidance recommended
*Hepatic dosing: dose reduction or avoidance recommended

==Contraindications==
*Allergy to class/drug
*Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks
*Seizure disorder
*Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, benzos, or AEDs, anorexia/bulimia, electrolyte derangement)

==Adverse Reactions==
===Serious===
*Seizure
*Cardiac dysrhythmia
*Angle-closure glaucoma
*Suicidal ideation, worsening depression, mania, psychosis
===Common===
*Insomnia
*Dizziness, tremor
*Headache
*Nausea, constipation
*Tachyarrhythmia (10.8% )
*Pruritus, rash, urticaria
*Arthralgia, myalgia
*Tinnitus
*Xerostomia, pharyngitis

==Pharmacology==
*Half-life: 14-33h
*Metabolism: Hepatic, CYP2B6
*Excretion: Mostly renal

==Mechanism of Action==
*Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine

==Comments==

==See Also==
*[[Bupropion toxicity]]

==References==
<references/>
[[Category:Pharmacology]]

Bupropion - Revision history

Elcatracho: /* Pediatric Dosing */

Elcatracho: /* Contraindications */

Elcatracho: /* Mechanism of Action */

Elcatracho: /* Pharmacology */

Elcatracho: /* Pharmacology */

Elcatracho: /* Mechanism of Action */

ClaireLewis at 21:39, 19 September 2019

Humanguy: edited dosage forms, strengths, routes of administration, trade names

ClaireLewis: Created page with "==Administration== *Type: Antidepressant *Dosage Forms: *Routes of Administration: oral *Common Trade Names: Wellbutrin, Zyban, Forfivo ==Adult Dosing== *Immediate release: 1..."

ClaireLewis: Created page with "==Administration== Type: Antidepressant Dosage Forms: Routes of Administration: oral Common Trade Names: Wellbutrin, Zyban, Forfivo ==Adult Dosing== *Immediate release: 1..."